Form 4: DarioHealth Director Matheis Awarded Shares

DarioHealth Corp. Director Dennis Matheis received a restricted share award of 20,000 common shares, bringing his total beneficial ownership to 27,631 shares, following a recent 20-for-1 reverse stock split.

Summary

• Dennis Matheis, a Director of DarioHealth Corp. (DRIO), was granted 20,000 shares of common stock.
• The transaction date for this award was September 11, 2025.
• These shares were awarded at a price of $0, indicating a grant rather than a purchase.
• Following this transaction, Matheis beneficially owns 27,631 shares of DarioHealth Corp. common stock.
• The reported beneficial ownership reflects a 20-for-1 reverse stock split that was effective on August 28, 2025.
• The restricted share award will vest on the last day of the second-year anniversary after the grant date.

Sentiment

Score: 7

Explanation: A director receiving a share award is generally positive as it aligns interests, though the reverse split context might temper enthusiasm, suggesting underlying challenges.

Positives

• Director Dennis Matheis received a restricted share award of 20,000 common shares, aligning his interests with shareholders.

Risks

• The company recently effected a 20-for-1 reverse stock split on August 28, 2025, which can sometimes indicate underlying challenges such as a low stock price or a need to meet exchange listing requirements.

Future Outlook

The restricted share award granted to Director Dennis Matheis is scheduled to vest on the last day of the second-year anniversary following the September 11, 2025 grant date.

Related Party Transactions

• Grant of 20,000 restricted common shares to Dennis Matheis, a Director of DarioHealth Corp.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value through equity ownership.
• Management/Directors: Dennis Matheis's compensation package includes equity, incentivizing long-term performance.

Next Steps

• Vesting of the 20,000 restricted shares on the last day of the second-year anniversary after the September 11, 2025 grant date.

Key Dates

Recommendation

The filing details a routine restricted share award to a director, which is a positive for aligning management incentives. However, the mention of a recent 20-for-1 reverse stock split, while not explicitly a negative in this Form 4, often signals underlying operational or financial challenges for a company. This context suggests a need for further due diligence beyond this insider transaction report. Therefore, a 'hold' recommendation is appropriate, pending a deeper analysis of the company's financial performance and strategic outlook.

Keywords

DRIO, DarioHealth, Dennis Matheis, Form 4, insider transaction, stock award, director compensation, restricted shares, reverse stock split